Coreg

(Carvedilol)

ApprovedSmall molecule

Carvedilol is used to treat high blood pressure and heart failure by helping the heart pump blood more efficiently and reducing strain on blood vessels.[2] Coreg is currently approved and in use across 39 indications[4].[1]

Coreg is one of 915 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

151

Total Trials

Active Trials

914

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Glioblastoma MultiformeApproved

Acute-on-Chronic Liver FailureActive, not recruiting

ProphylaxisCompleted

LymphomaApproved

Pulmonary HypertensionApproved

Multiple MyelomaApproved

Chronic Kidney DiseaseApproved

Post-Traumatic Stress DisorderApproved

EpilepsyApproved

Cardiovascular DiseaseApproved

Active, not recruiting

Glioblastoma MultiformeApproved

Approved

Acute-on-Chronic Liver FailurePreclinical

Active, not recruiting

ProphylaxisApproved

Completed

LymphomaApproved

Approved

Pulmonary HypertensionApproved

Approved

Multiple MyelomaApproved

Approved

Chronic Kidney DiseaseApproved

Approved

Post-Traumatic Stress DisorderApproved

Approved

EpilepsyApproved

Approved

Showing 10 of 39 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Coreg

Akero Therapeutics

Approved

4 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Duragesic

CCephalon

Preclinical

1 8

Tricor

JJagotec

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Esophageal Varices

NCT05872698

N/ARecruiting

Esophageal Varices

NCT01212250

Q1 2027

Phase 2Active, not recruiting

Breast Cancer

NCT03879629

Q3 2027

Phase 3Recruiting

Breast Cancer

NCT03418961

N/ANot yet recruiting

Cirrhosis

NCT07465471

Q1 2028

N/ARecruiting

Cardiomyopathy

NCT06431919

Clinical

Trials by Indication[1]

Heart Failure18 trials

Biomarker Guided Therapies in Stage A/B Heart Failure

Completed·VVA Office of Research and Development·Phase 2·NCT02230891·58 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

Therapy With Verapamil or Carvedilol in Chronic Heart Failure

Unknown status·MMedical University of Silesia·Phase 4·NCT00374465·100 enrolled

Show 15 more trials

Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure

Completed·MMichael E. DeBakey VA Medical Center·Phase 4·NCT01261065·55 enrolled

Heart Rate Reduction in Heart Failure

Completed·IIRCCS San Raffaele·Phase 3·NCT01178528·121 enrolled

Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

Completed·CCardiovascular Clinical Sciences Inc·Phase 3·NCT00272805·400 enrolled

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure

Completed·CCentro Cardiologico Monzino·Phase 4·NCT00517725·60 enrolled

The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)

Unknown status·MMebix Inc·N/A·NCT02137733·220 enrolled

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Not yet recruiting·UUniversity Hospital Ostrava·Phase 4·NCT06035978·100 enrolled

A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure

Completed· GSK logo

GSK·Phase 1·NCT00742508·41 enrolled

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

Completed·CCTI-1, LLC·Phase 3·NCT00323037·318 enrolled

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

Recruiting·UUniversity of Rochester·Phase 4·NCT06964464·2,000 enrolled

Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction

Unknown status·UUniversitas Sebelas Maret·Phase 4·NCT05179070·26 enrolled

A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure

Withdrawn·TThe Alfred·Phase 4·NCT00384566

Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction

Not yet recruiting·OOdense University Hospital··NCT04996550·5,600 enrolled

Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients

Unknown status·—·N/A·NCT02619526·62 enrolled

The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure

Completed·NNational Center for Research Resources (NCRR)·Phase 1·NCT00004854

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Recruiting·VVirginia Commonwealth University·Preclinical·NCT05194111·70 enrolled

Carvedilol17 trials

Carvedilol Post-intervention Long-term Administration in Large-scale Trial

Completed·TTakeshi Morimoto·Phase 4·NCT01155635·801 enrolled

Ramipril Versus Carvedilol in Duchenne and Becker Patients

Unknown status·—·Phase 4·NCT00819845·194 enrolled

Effect of Carvedilol on Exercise Performance in Fontan Patients

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02946892·26 enrolled

Show 14 more trials

Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions

Completed·—·Phase 1·NCT01064180·24 enrolled

Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol

Completed·SSeoul National University Hospital·Phase 1·NCT02286934·24 enrolled

Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition

Completed·IIPCA Laboratories Ltd.·Phase 1·NCT01577914·42 enrolled

Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00648622·50 enrolled

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

Completed· Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc·Phase 1·NCT00650416·50 enrolled

Carvedilol for Psychostimulant Dependence

Completed·UUniversity of Arkansas·Phase 2·NCT01171183·32 enrolled

Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00775619·40 enrolled

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

Terminated·UUniversity at Buffalo·Phase 4·NCT00430040·14 enrolled

Extension Study of Carvedilol RCT Study

Unknown status·—·N/A·NCT05021406·240 enrolled

Carvedilol Vascular Efficacy Trial

Completed·EElpen Pharmaceutical Co. Inc.··NCT01484327·415 enrolled

Carvedilol in HF With Preserved EF

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT05553314·100 enrolled

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

Completed·VVA Greater Los Angeles Healthcare System·Phase 4·NCT03370835·21 enrolled

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

Completed·—·Phase 3·NCT00129363·75 enrolled

Effects of Carvedilol on Cocaine Use in Humans - 11

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00000294

Hypertension9 trials

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

Completed· GSK logo

GSK·Phase 4·NCT00060931·501 enrolled

Conditioned Pharmacotherapeutic Effects in Hypertension

Completed·UUniversity of Rochester·Phase 4·NCT02056626·44 enrolled

A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

Terminated·EEgalet Ltd·Phase 2·NCT00444834·14 enrolled

Show 6 more trials

Mechanisms and Treatment of Intradialytic Hypertension

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT00827775·55 enrolled

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Completed·EEmory University·N/A·NCT02406586·36 enrolled

Mechanism of Masked Hypertension - Intervention

Withdrawn·UUniversity of Alabama at Birmingham·Phase 3·NCT04121299

Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study

Unknown status·YYoshio Matsui·Phase 4·NCT01243827·200 enrolled

Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

Unknown status· Ahn-Gook Pharmaceuticals Co.,Ltd logo

Ahn-Gook Pharmaceuticals Co.,Ltd·Phase 3·NCT01413048·260 enrolled

Mechanisms of Refractory Hypertension (Carvedilol)

Withdrawn·UUniversity of Alabama at Birmingham·N/A·NCT02357004

Portal Hypertension9 trials

Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis

Completed·CChangqing Yang·Phase 4·NCT02907749·96 enrolled

Danish Carvedilol Study in Portal Hypertension

Completed·HHvidovre University Hospital·Phase 3·NCT00493480·40 enrolled

Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05767229·40 enrolled

Show 6 more trials

Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension

Unknown status·—·Phase 3·NCT02975323·50 enrolled

Can MRI Evaluate Beta-blocker Response in Portal Hypertension?

Unknown status·UUniversity of Nottingham··NCT03114813·68 enrolled

The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis

Not yet recruiting·SShanghai Changzheng Hospital·Phase 2/3·NCT06470386·178 enrolled

Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension

Unknown status·UUniversidade Federal do Rio de Janeiro·Phase 2/3·NCT03720067·80 enrolled

WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis

Unknown status·SShanghai Changzheng Hospital··NCT03195634·80 enrolled

To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02465645·220 enrolled

Cirrhosis6 trials

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

Unknown status·UUnknown Sponsor·Phase 3·NCT04543643·288 enrolled

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT07322237·400 enrolled

Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis.

Recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07108075·72 enrolled

Show 3 more trials

Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03069339·330 enrolled

Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07465471·210 enrolled

Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT01059396·201 enrolled

60 more indications

Esophageal Varices6 trials

Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis

Recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01212250·132 enrolled

Carvedilol for Prevention of Esophageal Varices Progression

Unknown status·—·N/A·NCT03736265·240 enrolled

Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.

Recruiting·KKing's College Hospital NHS Trust·Phase 4·NCT05872698·1,200 enrolled

Show 3 more trials

Early Primary Prophylaxis of Esophageal Varices

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01196507·140 enrolled

Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05057572·104 enrolled

Beta-blockers for Oesophageal Varices

Unknown status·KKing's College Hospital NHS Trust·Phase 4·NCT03776955·1,200 enrolled

Prophylaxis4 trials

The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT02695732·792 enrolled

Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding

Recruiting·SSherief Abd-Elsalam·Phase 2/3·NCT04499898·306 enrolled

RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage

Unknown status·—·Phase 4·NCT01070641·148 enrolled

Show 1 more trial

Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding

Completed·KKaohsiung Veterans General Hospital.·Phase 4·NCT02504723·121 enrolled

Pulmonary Arterial Hypertension4 trials

PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)

Completed·TThe Cleveland Clinic·N/A·NCT01586156·30 enrolled

Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension

Completed·VVirginia Commonwealth University·Phase 1/2·NCT00964678·10 enrolled

Beta-blockers in Pulmonary Arterial Hypertension

Terminated·UUniversity of Minnesota·Phase 2·NCT02507011·2 enrolled

Show 1 more trial

Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children

Withdrawn·TThe Hospital for Sick Children·Phase 1/2·NCT01723371

Prevention4 trials

Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding

Terminated·—·Phase 4·NCT01383044·65 enrolled

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

Recruiting·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT06594744·120 enrolled

A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding

Completed·—·Phase 4·NCT01103154·121 enrolled

Show 1 more trial

HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic Patients

Unknown status·—·N/A·NCT04254822·220 enrolled

Cardiotoxicity4 trials

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02177175·82 enrolled

Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity

Completed·UUniversity of Sao Paulo·Phase 3·NCT01724450·200 enrolled

Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy

Unknown status·HHospital Sirio-Libanes·Phase 4·NCT04939883·1,018 enrolled

Show 1 more trial

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT06844669·7 enrolled

Breast Cancer4 trials

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT03418961·491 enrolled

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

Completed·—·Phase 1·NCT04023110·68 enrolled

A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging

Active, not recruiting·NNorthwestern University·Phase 2·NCT02993198·134 enrolled

Show 1 more trial

Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

Active, not recruiting·MMayo Clinic·Phase 2·NCT03879629·184 enrolled

Atrial Fibrillation3 trials

RATe Control in Atrial Fibrillation

Completed·—·Phase 3·NCT00313157·80 enrolled

Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation

Completed·—·Phase 3·NCT02832089·30 enrolled

Rate Control in Atrial Fibrillation

Unknown status·—·Phase 4·NCT02251509·20 enrolled

Cardiomyopathy3 trials

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Withdrawn·MMayo Clinic·Phase 2·NCT04190433

Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy

Not yet recruiting·—·Phase 1·NCT06304896·150 enrolled

Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival

Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT06431919·260 enrolled

Propranolol3 trials

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding

Unknown status·WWest China Hospital·N/A·NCT05651789·160 enrolled

Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices

Enrolling by invitation·XXijing Hospital·Phase 4·NCT07352228·350 enrolled

The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT02385422·480 enrolled

Liver Disease2 trials

Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02294292·189 enrolled

Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

Recruiting·—·Phase 4·NCT06449339·474 enrolled

Parkinson's Disease2 trials

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

Active, not recruiting·—·Phase 2·NCT04218968·15 enrolled

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

Active, not recruiting·—·Phase 2·NCT03775096·15 enrolled

Glioblastoma2 trials

Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells

Terminated·WWest Virginia University·Phase 1·NCT03861598·4 enrolled

Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells

Withdrawn·WWest Virginia University·Phase 1·NCT03980249

Fasting Conditions2 trials

Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions

Completed·—·Phase 1·NCT01064154·36 enrolled

Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00776113·40 enrolled

Adult Subject2 trials

Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects

Completed· Teva logo

Teva·Phase 1·NCT00834873·24 enrolled

Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects

Completed· Teva logo

Teva·Phase 1·NCT00834795·36 enrolled

Hepatocellular Carcinoma2 trials

Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06836778·100 enrolled

Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01659346

Pulmonary Function1 trial

Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.

Completed·IIstituto Auxologico Italiano·Phase 4·NCT00924833·27 enrolled

Adenocarcinoma1 trial

Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate

Unknown status·MMontefiore Medical Center·Phase 2·NCT02944201·22 enrolled

Duchenne Muscular Dystrophy1 trial

The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy

Unknown status·—·Phase 4·NCT00606775·60 enrolled

Diagnosis1 trial

Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS

Unknown status·CChangqing Yang·Phase 4·NCT02925975·100 enrolled

Diabetes Mellitus1 trial

Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension

Completed· GSK logo

GSK·Phase 4·NCT00060918·1,210 enrolled

Coronary Artery Disease1 trial

The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

Completed·FForest Laboratories·Phase 4·NCT00673075·39 enrolled

Paroxysmal atrial fibrillation1 trial

Carvedilol for Prevention of Paroxysmal Atrial Fibrillation

Unknown status·UUniversity of Calgary·N/A·NCT01608893·300 enrolled

Sickle Cell Disease1 trial

Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease

Withdrawn·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT01568645

Rheumatoid Arthritis1 trial

Clinical Study Evaluating the Effect of Carvedilol in Patients With Active Rheumatoid Arthritis

Not yet recruiting·TTanta University·Phase 1·NCT06108518·70 enrolled

Nephropathy1 trial

Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.

Completed·Rrabab ahmed mohamed·Phase 2·NCT03867994·144 enrolled

Moderate to Severe COPD1 trial

Beta Blocker Therapy in Moderate to Severe COPD

Completed·UUniversity of Dundee·Phase 4·NCT01656005·18 enrolled

Gastric Varices1 trial

The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices

Unknown status·SShanghai Zhongshan Hospital·Phase 4·NCT02638415·500 enrolled

Myocardial Infarction1 trial

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Active, not recruiting·—·Phase 4·NCT03778554·2,760 enrolled

Angina Pectoris1 trial

Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris

Completed·GGachon University Gil Medical Center·Phase 4·NCT02547597·99 enrolled

Heart Disease1 trial

Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy

Unknown status·TTanta University·N/A·NCT05553717·66 enrolled

Gene Expression1 trial

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

Completed·UUniversity of Colorado, Denver·Phase 4·NCT01798992·56 enrolled

Ischemia1 trial

Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol

Unknown status·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT01425164·220 enrolled

Drug Metabolism1 trial

KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism

Completed·HHelsinki University Central Hospital·N/A·NCT06566794·12 enrolled

Cardiovascular1 trial

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

Recruiting·VVA Office of Research and Development·Phase 3·NCT05931276·2,540 enrolled

Alzheimer's Disease1 trial

Trial of Carvedilol in Alzheimer's Disease

Completed·JJohns Hopkins University·Phase 4·NCT01354444·29 enrolled

Acute Coronary Syndrome1 trial

Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome

Completed·FFederico II University·Phase 4·NCT02809820·100 enrolled

Congestive Heart Failure1 trial

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

Completed·—·Phase 3·NCT00052026·161 enrolled

Childhood Cancer1 trial

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Completed·CChildren's Oncology Group·Phase 2·NCT02717507·196 enrolled

Efficacy and Safety1 trial

Carvedilol PAH A Pilot Study of Efficacy and Safety

Terminated·UUniversity of Minnesota·Phase 1·NCT02120339·5 enrolled

Type 2 Diabetes1 trial

Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes

Completed·SSt. Paul Heart Clinic·Phase 4·NCT00123604·36 enrolled

Adjuvant1 trial

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Recruiting·UUniversity of Arizona·Phase 1·NCT06643221·100 enrolled

Hypoglycemia1 trial

Carvedilol in Treating Hypoglycemia Unawareness

Terminated·OOwen Chan, PhD·Phase 2·NCT03538015·1 enrolled

Withdrawal1 trial

Cocaine Withdrawal and Pharmacotherapy Response

Completed·YYale University·N/A·NCT00566969·106 enrolled

Chronic Liver Failure1 trial

Acute Hemodynamic Response to Carvedilol in Predicting Survival in Acute on Chronic Liver Failure Patients - A Pilot Study.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05180292·50 enrolled

Humans1 trial

Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans

Completed·GGitte Moos Knudsen·Phase 1·NCT03576664·22 enrolled

Hypertensive1 trial

Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients

Completed·KKafrelsheikh University·Phase 4·NCT07397481·40 enrolled

Bariatric Surgery1 trial

Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol

Unknown status·NNatalia Valadares de Moraes·Phase 4·NCT04049786·120 enrolled

Ventricular Tachycardia1 trial

Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract

Unknown status·KKeimyung University Dongsan Medical Center·Phase 4·NCT03587558·104 enrolled

Brain Injury1 trial

Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in Patients With Traumatic Brain Injury

Recruiting·MMansoura University·Phase 1/2·NCT06836856·100 enrolled

Post-Traumatic Stress Disorder, PTSD1 trial

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

Unknown status·CColumbia Northwest Pharmaceuticals·Phase 2·NCT01221792·80 enrolled

New Onset1 trial

Use of Beta-blockers and Risk of New Onset Diabetes

Completed· GSK logo

GSK··NCT01587638·12,336 enrolled

Completed·UUniversity of New Mexico·Phase 4·NCT00642434·22 enrolled

Combination Therapy1 trial

Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding

Withdrawn·RRutgers, The State University of New Jersey·Phase 3·NCT02066649

Methamphetamine1 trial

Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT01270672·16 enrolled

Ultrasound1 trial

CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound

Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT06861075·30 enrolled

Cardiac Dysfunction1 trial

Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.

Unknown status·MMakerere University·Phase 3·NCT03542058·50 enrolled

Monotherapy1 trial

Pentoxifylline Plus Carvedilol vs Carvedilol Monotherapy in Preventing New Decompensation in Stable Cirrhotic Patients With Prior Decompensation

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06041932·180 enrolled

Unspecified1 trial

Pharmacological Reduction of Right Ventricular Enlargement

Completed·—·Phase 3·NCT04345796·56 enrolled

Regulatory

FDA Approval Timeline[5]

May 29, 1997

COREG

NDA NDA020297

Oct 20, 2006

COREG CR

NDA NDA022012

Sources

References

[1]
ClinicalTrials.gov — 151 trial records for Carvedilol. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Coreg drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Carvedilol compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Carvedilol. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022012). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Coreg. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Adrenergic Receptor Alpha-1 Antagonist; Adrenergic Receptor Beta Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Akero Therapeutics

Patent Landscape[6]

Patent #Expires

8101209Sep 11, 2025

8101209*PEDMar 11, 2026

Coreg

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q1 2028

Trials by Indication[1]

Heart Failure18 trials

Carvedilol17 trials

Hypertension9 trials

Portal Hypertension9 trials

Cirrhosis6 trials

Esophageal Varices6 trials

Prophylaxis4 trials

Pulmonary Arterial Hypertension4 trials

Prevention4 trials

Cardiotoxicity4 trials

Breast Cancer4 trials

Atrial Fibrillation3 trials

Cardiomyopathy3 trials

Propranolol3 trials

Liver Disease2 trials

Parkinson's Disease2 trials

Glioblastoma2 trials

Fasting Conditions2 trials

Adult Subject2 trials

Hepatocellular Carcinoma2 trials

Pulmonary Function1 trial

Adenocarcinoma1 trial

Duchenne Muscular Dystrophy1 trial

Diagnosis1 trial

Diabetes Mellitus1 trial

Coronary Artery Disease1 trial

Paroxysmal atrial fibrillation1 trial

Sickle Cell Disease1 trial

Rheumatoid Arthritis1 trial

Nephropathy1 trial

Moderate to Severe COPD1 trial

Gastric Varices1 trial

Myocardial Infarction1 trial

Angina Pectoris1 trial

Heart Disease1 trial

Gene Expression1 trial

Ischemia1 trial

Drug Metabolism1 trial

Cardiovascular1 trial

Alzheimer's Disease1 trial

Acute Coronary Syndrome1 trial

Congestive Heart Failure1 trial

Childhood Cancer1 trial

Efficacy and Safety1 trial

Type 2 Diabetes1 trial

Adjuvant1 trial

Hypoglycemia1 trial

Withdrawal1 trial

Chronic Liver Failure1 trial

Humans1 trial

Hypertensive1 trial

Bariatric Surgery1 trial

Ventricular Tachycardia1 trial

Brain Injury1 trial

Post-Traumatic Stress Disorder, PTSD1 trial

New Onset1 trial

Acute-on-Chronic Liver Failure1 trial

Function1 trial

Blood Pressure1 trial

Combination Therapy1 trial

Methamphetamine1 trial

Ultrasound1 trial

Cardiac Dysfunction1 trial

Monotherapy1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News